Parkinson’s Disease

Parkinson’s Disease

 

 

Adams JD Jr., Klaidman LK, Odunze IN, Shen HC, Miller CA. Alzheimer’s and Parkinson’s disease. Brain levels of glutathione, glutathione disulfide, and vitamin E. Molecular Chemistry Neuropathology 14(3);213-226, 1991 Medline

Adams JD Jr., Odunze IN. Oxygen free radicals and Parkinson’s disease. Free Radical Biol Med 10(2):161-169, 1991 Medline

Di Monte DA, Chan P, Sandy MS. Glutathione in Parkinson’s disease: a link between oxidative stress and mitochondrial damage? Annals of Neurology 32(suppl):S111-115, 1992 Medline

Ebadi M, Srinivasan SK, Baxi MD. Oxidative stress and antioxidant therapy in Parkinson’s disease. Progress in Neurobiology 48(1): 1-19, 1996 Medline

Gabby M, Tauber M, Porat S, Simantov R. Selective role of glutathione in protecting human neuronal cells from dopamine-induced apoptosis. Neuropharmacology 35(5):571-578, 1996 Medline

Jenner P. Oxidative damage in neurodegenerative disease. Lancet 17:796-798, 1994 Medline

Jenner P. Oxidative stress in Parkinson’s disease and other neurodegenerative disorders. Pathol Biol 44(1):57-64, 1996 Medline

Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology 47(6 suppl3):S161-S170, 1996 Medline

Owen AD, Schapira AHV, Jenner P, Marsden CD. Oxidative stress and Parkinson’s disease. Annals of the New York Academy of Science 786:217-223, 1996 Medline

Offen D, Ziv I, Sternin H, Melamed E, Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson’s disease. Experimental Neurology 141(1):32-39, 1996 Medline

Perry TL, Godin DV, Hansen S. Parkinson’s disease: a disorder due to nigral GSH deficiency? Neuroscience Letter 33(3):305-310, 1982 Medline

Reiderer P, Sofic E, Rausch WD, Schmidt B. Transition metals, ferritin, GSH, ascorbic acid in Parkinsonian Brains. Journal of Neurochemistry 52:515-520, 1989 Medline

Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM, Rosati G. Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry 20(7):1159-70, 1996 Medline

Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD. Glutathione-related enzymes in brain in Parkinson’s disease. Annals of Neurology 36(3)356-361, 1994 Medline

Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD. Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Annals of Neurology 36(3):348-355, 1994 Medline

Simonian NA, Coyle JT. Oxidative stress in neurodegenerative diseases. Annual Review of Pharmacology & Toxicology 36:83-106, 1996 Medline 

Spencer JP, Jenner P, Halliwell B. Superoxide-dependent depletion of reduced glutathione by L-Dopa and dopamine. Relevance to Parkinson’s disease. Neuroreport 6(11): 1480-84, 1995 Medline

Zhang F. Dryhurst G. Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson’s disease. Journal of Medical Chemistry 37(8);1084-98, 1994 Medline

Leave a Reply

(required)

(required)